Abstract
Glioblastoma is a poorly immunogenic cancer and treatment options for recurrent glioblastoma are limited. Therefore, there is an urgent need for effective treatment strategies against recurrent glioblastoma. Here, we investigated a new treatment combination based on the tumor-stroma targeting antibody-cytokine fusion protein L19TNF and the alkylating chemotherapy lomustine in preclinical glioma models and patients with recurrent glioblastoma.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call